Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Assets: 2020-2025

Historic Assets for Relay Therapeutics (RLAY) over the last 6 years, with Sep 2025 value amounting to $670.0 million.

  • Relay Therapeutics' Assets fell 27.97% to $670.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $670.0 million, marking a year-over-year decrease of 27.97%. This contributed to the annual value of $871.3 million for FY2024, which is 3.24% up from last year.
  • Per Relay Therapeutics' latest filing, its Assets stood at $670.0 million for Q3 2025, which was down 8.07% from $728.8 million recorded in Q2 2025.
  • Over the past 5 years, Relay Therapeutics' Assets peaked at $1.2 billion during Q3 2022, and registered a low of $670.0 million during Q3 2025.
  • Moreover, its 3-year median value for Assets was $844.0 million (2023), whereas its average is $851.3 million.
  • Its Assets has fluctuated over the past 5 years, first soared by 105.27% in 2021, then decreased by 27.97% in 2025.
  • Relay Therapeutics' Assets (Quarterly) stood at $1.0 billion in 2021, then rose by 9.06% to $1.1 billion in 2022, then declined by 23.26% to $844.0 million in 2023, then rose by 3.24% to $871.3 million in 2024, then fell by 27.97% to $670.0 million in 2025.
  • Its Assets was $670.0 million in Q3 2025, compared to $728.8 million in Q2 2025 and $799.4 million in Q1 2025.